Syeda Seirut Javed
1 min read
In This Article:
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is one of the 16 stocks Jim Cramer recently discussed. A caller asked if it was a good time to buy the stock. Cramer replied:
“You know what? I like their model… and I think that, well, here’s what I look at, it’s a great flier. Someone needs that technology, someone’s going to pay for it.”
A laboratory technician processing a batch of medication in an industrial setting.
ARS Pharmaceuticals (NASDAQ:SPRY) is a biopharmaceutical company focused on helping patients and caregivers manage severe allergic reactions, with its product neffy, a nasal epinephrine spray approved for emergency treatment of anaphylaxis in both the U.S. and EU.
In the first quarter of 2025, the company reported $8.0 million in total revenue. The net loss for the quarter was $33.9 million, or $0.35 per share. Moreover, as of March 31, ARS Pharmaceuticals (NASDAQ:SPRY) held $275.7 million in cash, cash equivalents, and short-term investments. It maintained its outlook that current financial resources are expected to support operations for at least the next three years.
While we acknowledge the potential of SPRY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
